SynthesisClinics (Sao Paulo, Brazil)
Partial prostatectomy in prostate cancer: a systematic review of current evidence.
Synthesis in Clinics (Sao Paulo, Brazil). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the current evidence in the literature about partial prostatectomy as a treatment for localized prostate cancer.
methodsA systematic search of nine databases was conducted up to December 2024 to identify studies involving patients with localized prostate cancer who underwent partial prostatectomy reporting clinical epidemiological characteristics, diagnostic strategies, histopathological findings, tumor staging, functional and oncological outcomes. The primary outcome was biochemical recurrence rate. Secondary outcomes were overall survival, disease-free survival, erectile dysfunction, urinary incontinence, and perioperative complications. The extracted data were systematically synthesized.
resultsThe authors analyzed five studies with a total of 48 patients (three prospective and two retrospective), all with low- or intermediate-risk disease. The mean surgical duration ranged from 129.2 to 208 min, with a single Clavien-Dindo Grade III complication reported. Only one study defined and reported biochemical recurrence, with a rate of 28 %. Urinary continence was preserved in 92 %-100 % of cases, while erectile function in 40 %-100 % ‒ which may represent a point of concern for this procedure. Overall survival and disease-free survival were consistently reported at 100 %. The lack of standardized reporting and the absence of randomized clinical trials prevented the performance of a meta-analysis and hindered the applicability of the findings to clinical practice.
conclusionRandomized clinical trials are still needed to provide stronger evidence regarding partial prostatectomy, as current data remain insufficient to support its routine use. With further research, partial prostatectomy may become an option for patients with favorable and intermediate-risk disease with unilateral lesions and concordance between magnetic resonance imaging and biopsy findings. Until then, radical prostatectomy remains the cornerstone of treatment for this patient profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.